<DOC>
	<DOC>NCT00664898</DOC>
	<brief_summary>This is an open-label, multicenter, Phase Ib study to be conducted at approximately eight sites in Europe and the U.S. designed to evaluate the safety, pharmacokinetics, and activity of SGN-40 when combined with bortezomib in patients with multiple myeloma that is relapsed or refractory after at least one prior systemic treatment regimen.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Age ≥ 18 years Documented pathologic diagnosis of multiple myeloma that has relapsed or failed to respond after treatment with at least one prior systemic therapy (other than corticosteroid monotherapy) Measurable disease At least one prior systemic therapy other than singleagent corticosteroids European Union patients must have had prior bone marrow transplant (autologous) or be ineligible for transplant If previously received bortezomib, demonstration of clinical response of any duration or stable disease with progressionfree interval of ≥ 6 months from the start of that therapy If previously received bortezomib, must have recovered from bortezomibrelated toxicities and must have a peripheral neuropathy score of Grade ≤ 1, according to the NCI CTCAE v3.0 If applicable, completion of autologous transplant ≥ 12 weeks prior to Day 1 Discontinuation of previous anticancer or investigational therapy for ≥ 21 days prior to treatment, or ≥ 90 days prior to treatment for previous monoclonal antibody administration Prior allogeneic bone marrow transplant Other invasive malignancies within 3 years prior to Day 1 except for adequately treated basal cell or squamous cell skin cancer; carcinoma in situ of the cervix, breast, or prostate; or other cancer of which the patient has been diseasefree for ≥ 3 years Prior anaphylactic reaction to human immunoglobulin administration Symptomatic hyperviscosity syndrome Active infection requiring parenteral antibiotics within 14 days of Day 1 Major surgical procedure or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study Clinically significant cardiac dysfunction or other significant organ dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>anti-CD40</keyword>
	<keyword>Myeloma</keyword>
</DOC>